Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL335584 | 0.80 | PKM (0.43) | MEN1KMT2AMMP8PKMKDM4E | |
| SCHEMBL3737736 | 0.77 | MMP8 (0.41) | MEN1KMT2AMMP8PKMKDM4E | |
| SCHEMBL11136882 | 0.76 | MMP8 (0.40) | MEN1KMT2AMMP8PKMKDM4E | |
| SCHEMBL13287418 | 0.74 | MMP8 (0.39) | MEN1KMT2AMMP8PKMKDM4E | |
| SCHEMBL2438993 | 0.74 | MMP8 (0.39) | MEN1KMT2AMMP8PKMKDM4E | |
| SCHEMBL10655712 | 0.70 | CYP4F2 (0.46) | MEN1KMT2AMMP8PKMKDM4E | |
| SCHEMBL14815133 | 0.69 | ALOX15 (0.47) | KMT2A | |
| SCHEMBL20211699 | 0.68 | MEN1 (0.53) | MEN1KMT2AMMP8PKMKDM4E | |
| SCHEMBL14825973 | 0.68 | GGPS1 (0.47) | KMT2A | |
| SCHEMBL10836349 | 0.67 | PKM (0.41) | MEN1KMT2AMMP8PKMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834009-B2 | 4-hydroxy-5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834009-B2 | 4-hydroxy-5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834009-B2 | 4-hydroxy-5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-20090062263-A1 | treating hepatitis C virus infections; inhibitor of HCV NS5B polymerase; N-{3-[1-(4-Fluoro-benzyl)-4-hydroxy-5-(3-methyl-butyl)-2-oxo-1,2,5,6-tetrahydro-pyridin-3-yl]-1,1-dioxo-1,4-dihydro-1(lambda 6)-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide; coadministering with additional therapeutic agent | ANADYS PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | disclosed |
| US-20090062263-A1 | treating hepatitis C virus infections; inhibitor of HCV NS5B polymerase; N-{3-[1-(4-Fluoro-benzyl)-4-hydroxy-5-(3-methyl-butyl)-2-oxo-1,2,5,6-tetrahydro-pyridin-3-yl]-1,1-dioxo-1,4-dihydro-1(lambda 6)-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide; coadministering with additional therapeutic agent | ANADYS PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | disclosed |
| US-20090062263-A1 | treating hepatitis C virus infections; inhibitor of HCV NS5B polymerase; N-{3-[1-(4-Fluoro-benzyl)-4-hydroxy-5-(3-methyl-butyl)-2-oxo-1,2,5,6-tetrahydro-pyridin-3-yl]-1,1-dioxo-1,4-dihydro-1(lambda 6)-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide; coadministering with additional therapeutic agent | ANADYS PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062263-A1 | treating hepatitis C virus infections; inhibitor of HCV NS5B polymerase; N-{3-[1-(4-Fluoro-benzyl)-4-hydroxy-5-(3-methyl-butyl)-2-oxo-1,2,5,6-tetrahydro-pyridin-3-yl]-1,1-dioxo-1,4-dihydro-1(lambda 6)-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide; coadministering with additional therapeutic agent | HAVCR2, TPMT, CYP2B6 | MEN1 4690/4885KMT2A 2911/4885MMP8 2564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.